Potential Cardiovascular Blockbuster Inclisiran Among New Filings At EMA
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib